Abstract
Women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are subject to several complications during pregnancy, including reactivation of SLE, thrombosis, miscarriage, neonatal lupus, pregnancy-induced hypertension, pulmonary hypertension and drug toxicity. Correct management of these patients requires combined medical-obstetric care, close surveillance of baby's growth and well-being, control of SLE activity and correct thromboprophylaxis. With good care, most pregnancies in women with SLE and APS end successfully.
MeSH terms
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects
-
Antiphospholipid Syndrome / diagnosis*
-
Antiphospholipid Syndrome / drug therapy
-
Antiphospholipid Syndrome / immunology
-
Aspirin / adverse effects
-
Aspirin / therapeutic use
-
Disease Progression
-
Female
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Infant, Newborn
-
Lupus Erythematosus, Systemic / diagnosis*
-
Lupus Erythematosus, Systemic / drug therapy
-
Lupus Erythematosus, Systemic / immunology
-
Pregnancy
-
Pregnancy Outcome
-
Risk Factors
-
Thrombophilia / diagnosis
-
Thrombophilia / drug therapy
-
Thrombophilia / immunology
Substances
-
Anticoagulants
-
Immunosuppressive Agents
-
Aspirin